Claims for Patent: 10,392,442

Summary for Patent: 10,392,442

Title:	Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
Abstract:	This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.
Inventor(s):	Coric; Vladimir (Madison, CT), Keler; Tibor (Pipersville, PA), Davis; Thomas (Centreville, MD)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ) Celldex Therapeutics, Inc. (Hampton, NJ)
Application Number:	15/384,205
Patent Claims:	1. A method for treating a subject afflicted with a tumor comprising administering the subject in need thereof an antibody or an antigen-binding portion thereof that binds specifically to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity ("an anti-PD-1 antibody") in combination with varlilumab, wherein the anti-PD-1 antibody is selected from the group consisting of nivolumab, pembrolizumab, MEDI0680, and BGB-A317. 2. The method of claim 1, wherein the tumor is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof. 3. The method of claim 2, wherein the lung cancer is non-small cell lung cancer (NSCLC). 4. The method of claim 1, wherein the tumor is colon cancer. 5. The method of claim 1, wherein the tumor is PD-L1 positive. 6. The method of claim 1, further comprising measuring PD-L1 expression in the tumor. 7. The method of claim 1, wherein the anti-PD-1 antibody is nivolumab. 8. The method of claim 1, wherein the anti-PD-1 antibody is pembrolizumab. 9. The method of claim 1, wherein the anti-PD-1 antibody is administered at a dose ranging from at least about 0.1 mg/kg to at least about 10.0 mg/kg body weight once about every 1, 2 or 3 weeks. 10. The method of claim 9, wherein the anti-PD-1 antibody is administered at a dose of at least about 3 mg/kg body weight once about every 2 weeks. 11. The method of claim 1, wherein the varlilumab is administered at a dose ranging from at least about 0.01 mg/kg to at least about 10 mg/kg body weight once about every 1, 2 or 3 weeks. 12. The method of claim 11, wherein the varlilumab is administered at a dose of 0.1 mg/kg body weight, 1 mg/kg body weight, or 10 mg/kg body weight once about every 2 weeks. 13. The method of claim 1, wherein the anti-PD-1 antibody and the varlilumab are formulated for intravenous administration. 14. The method of claim 1, wherein the anti-PD-1 antibody and the varlilumab are administered sequentially, concurrently in separate compositions, or concurrently as a single composition. 15. The method of claim 1, wherein the anti-PD-1 antibody is administered at a flat dose of about 200 mg, about 240 mg, about 400 mg, or about 480 mg. 16. The method of claim 15, wherein the anti-PD-1 antibody is administered once about every 2 weeks, once about every 3 weeks, or once about every 4 weeks. 17. The method of claim 7, wherein the nivolumab is administered at a flat dose of about 240 mg once about every 2 weeks. 18. The method of claim 7, wherein the nivolumab is administered at a flat dose of about 480 mg once about every 4 weeks. 19. The method of claim 8, wherein the pembrolizumab is administered at a flat dose of about 200 mg once about every 3 weeks. 20. The method of claim 1, further comprising administering an anti-cancer agent.

Details for Patent 10,392,442

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	For Injection	125514	09/04/2014		2035-12-17
Merck Sharp & Dohme Corp.	KEYTRUDA	pembrolizumab	Injection	125514	01/15/2015		2035-12-17
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	12/22/2014		2035-12-17